The currently evolving novel therapies for the management of hemophilia has ushered in a new era characterized by improved prophylaxis targets and outcomes.
In this session from the WFH 2020 Virtual Summit, Johnny Mahlangu, Victor Blanchette, Robert Klamroth and Emna Gouider redefine prophylaxis in the modern era by revisiting its definition, presenting data to support higher trough levels to achieve through prophylaxis, and introducing steady-state hemostasis as a possible new target for prophylaxis. The benefits of low-dose prophylaxis will also be discussed.
Click on the icon below to access more on-demand Virtual Summit recordings.
